17 Innovators Highlight Investment to Solve Global Water Challenges
Seventeen organizations have joined forces to support the United Nations (UN) Water Action Agenda, pledging to invest $11 billion in water innovation over the next five years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230322005481/en/
Innovators highlight investment to solve global water challenges (Photo: Business Wire)
The collective commitment will be announced later today at an event organized by water technology company Xylem (NYSE: XYL) and the Kingdom of the Netherlands, convened during the UN 2023 Water Conference. The pledges will be included in the Water Action Agenda, a collection of all water-related commitments to accelerate progress on UN Sustainable Development Goal 6 targeting Water and Sanitation.
Executives from Xylem, Veolia, XPV, Hydraloop International, and Hansgrohe will be joined by several nonprofit organizations, to pledge their commitment to invest in innovative water solutions. The funds will be directed toward water-related research and development, start-up companies commercializing innovative approaches to water management, and the deployment of new water technologies. The organizations will also commit to ongoing engagement with development agencies, governments, and other stakeholders to facilitate more cross-sector action to solve water challenges.
“Most of humanity’s challenges today stem from our reliance on water, whether for human life or, on a larger scale, economic well-being and prosperity of society,” said Henk Ovink, Water Envoy of the Kingdom of the Netherlands. “We all need it, but in some places there is too much and in other places there isn’t enough. As significant water investors and users, the private sector has a pivotal role to play. The organizations pledging their commitment today are at the forefront of bringing new innovations to water use, treatment, and recycling. This type of collective action is essential to tackling major water challenges, and to creating a sustainable planet for future generations.”
The commitment from the private and philanthropic sectors to invest in water solutions supports the UN 2023 Water Conference’s call for clear pledges and actions, across all sectors, industries, and interests to achieve the UN Sustainable Development Goals.
“For those who can simply turn on a tap, water may not seem like a problem,” said Patrick Decker, CEO of Xylem. “But the UN 2023 Water Conference is a timely reminder that water challenges are intensifying around the world. The organizations making commitments today recognize these are challenges we can and must solve. Many of the essential technologies already exist, but as climate change progresses, we need more innovative solutions and accelerated implementation to increase the resilience and water-security of communities everywhere.”
The inclusion of the private sector in the UN 2023 Water Conference, the first event of its kind since 1977, has been welcomed as essential in developing an impactful Water Action Agenda. The conference brings together stakeholders from across governments, the private sector, non-governmental organizations, nonprofits, academic institutions, and the scientific community to advance transformative ideas that can solve global water challenges.
Organizations contributing to the pledge include Acciona, Autodesk, BlueTech, Burnt Island Ventures, The Coca-Cola Foundation, Evoqua, Grundfos, Hansgrohe, Hydraloop, Idexx, UGSI Solutions, Veolia, Water Foundry Ventures, Wavin, Westly Group, XPV and Xylem.
The event - Private Sector Investment Commitment to Water Innovation - will convene technology innovators, investors, government, civil society, and development agencies to consider the role of innovation in advancing the UN Sustainable Development Goals. Organized by Xylem and the Consulate General of the Kingdom of the Netherlands in New York, the event will be hosted in partnership with Bluetech Research, Burnt Island Ventures, Evoqua, the International Water Association, Mercy Corps, UNICEF, the Water Foundry, Veolia, the WateReuse Association, and the Water Research Foundation.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 17,000 diverse employees delivered revenue of $5.5 billion in 2022. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230322005481/en/
Contact information
Houston Spencer
+1 (914) 323-5723
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom